Clinical Trials Browser

Phase 1 × Mesothelioma × trametinib × Clear all

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

Mesothelioma, Neoplasms